Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Viatris Launches New Headquarters in Tokyo
April 6, 2021
- Toho to Supply Nafamostat Free of Charge to Italian Physician-Led COVID-19 Trial
April 6, 2021
- Mochida’s Updated 3-Year Biz Plan Vows Continued Focus on New Meds
April 5, 2021
- Suzuken Unit Wins Wholesale Contract for Incyte’s Pemazyre
April 5, 2021
- Taiho’s Cholangiocarcinoma Drug Gets Breakthrough Therapy Tag from FDA
April 5, 2021
- Houng Kim to Lead Celltrion Healthcare Japan
April 5, 2021
- Takeda/CSL-Led Alliance’s COVID-19 Plasma Therapy Fails in PIII
April 5, 2021
- GSK Sees Promise in Antibody Therapy against Coronavirus Variants, Looking at Japan Rollout Too
April 2, 2021
- Alinamin Aims for Growth via Retail Promotion, Full Entry into Asia: President
April 2, 2021
- ASKA Sets Up Office in London
April 2, 2021
- Takeda Wraps Up Divestment of European OTC Biz
April 2, 2021
- Takeda Completes Divestment of 4 Diabetes Meds to Teijin in Japan
April 2, 2021
- Mitsubishi Tanabe Wins US Patent Suit on Canagliflozin
April 2, 2021
- Viatris, Astellas to Wind Up Lipitor Copromotion at July-End
April 2, 2021
- Sandoz Shooting for Top Foreign Player in Japan Generic Market by 2023
April 1, 2021
- Fujifilm Holdings Names Teiichi Goto New President
April 1, 2021
- Eisai Snags Rights to Vibegron in 4 ASEAN States
April 1, 2021
- Takeda Completes Divestment of Consumer Healthcare Unit to Blackstone
April 1, 2021
- Eisai/MSD File Lenvima-Keytruda Pair in Japan, Seeking 1st Nod for RCC
April 1, 2021
- Opdivo Filed as Adjuvant for Resected Urothelial Cancer in Japan
April 1, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…